DE60121808D1 - Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen - Google Patents

Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen

Info

Publication number
DE60121808D1
DE60121808D1 DE60121808T DE60121808T DE60121808D1 DE 60121808 D1 DE60121808 D1 DE 60121808D1 DE 60121808 T DE60121808 T DE 60121808T DE 60121808 T DE60121808 T DE 60121808T DE 60121808 D1 DE60121808 D1 DE 60121808D1
Authority
DE
Germany
Prior art keywords
inflammation
treatment
extracellular domain
polypeptide containing
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60121808T
Other languages
English (en)
Other versions
DE60121808T2 (de
Inventor
A Chandrasekher
R Jaspers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of DE60121808D1 publication Critical patent/DE60121808D1/de
Publication of DE60121808T2 publication Critical patent/DE60121808T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60121808T 2000-09-15 2001-09-13 Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen Expired - Lifetime DE60121808T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23330500P 2000-09-15 2000-09-15
US233305P 2000-09-15
PCT/US2001/028557 WO2002022153A2 (en) 2000-09-15 2001-09-13 Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation

Publications (2)

Publication Number Publication Date
DE60121808D1 true DE60121808D1 (de) 2006-09-07
DE60121808T2 DE60121808T2 (de) 2007-03-29

Family

ID=22876714

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60141546T Expired - Lifetime DE60141546D1 (de) 2000-09-15 2001-09-13 Polypeptide enthaltend extrazellulären Domäne von IL-20RA und/oderr IL-20RB
DE60121808T Expired - Lifetime DE60121808T2 (de) 2000-09-15 2001-09-13 Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60141546T Expired - Lifetime DE60141546D1 (de) 2000-09-15 2001-09-13 Polypeptide enthaltend extrazellulären Domäne von IL-20RA und/oderr IL-20RB

Country Status (10)

Country Link
US (2) US7855269B2 (de)
EP (2) EP1803733B1 (de)
JP (1) JP4908723B2 (de)
AT (2) ATE333888T1 (de)
AU (1) AU2001290837A1 (de)
CA (1) CA2422033A1 (de)
DE (2) DE60141546D1 (de)
DK (1) DK1351703T3 (de)
ES (1) ES2267814T3 (de)
WO (1) WO2002022153A2 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
JP5015404B2 (ja) * 2000-08-08 2012-08-29 ザイモジェネティクス， インコーポレイテッド 可溶性ｚｃｙｔｏｒ１１サイトカイン受容体
EP1803733B1 (de) * 2000-09-15 2010-03-10 ZymoGenetics, Inc. Polypeptide enthaltend extrazellulären Domäne von IL-20RA und/oderr IL-20RB
BRPI0408705A (pt) * 2003-03-24 2006-03-07 Zymogenetics Inc método para produzir um anticorpo para um polipeptìdeo, anticorpo produzido pelo mesmo, anticorpo ou fragmento de anticorpo que se liga a um polipeptìdeo, métodos para reduzir ou inibir a proliferação ou diferenciação induzida pela il-20 de células hematopoiéticas e progenitores de célula hematopoiética, para reduzir a inflamação induzida pela il-20, para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero afligido com uma doença inflamatória, para tratar um condição patológica em um paciente associada com a atividade de il-20
US20040248097A1 (en) * 2003-05-23 2004-12-09 Ming-Shi Chang Interleukin-20 variants and promoters
JP2007501813A (ja) * 2003-08-08 2007-02-01 ノボ　ノルディスク　アクティーゼルスカブ 新生血管形成と関連した症状を治療および診断するためのインターロイキン−２０
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
WO2005052001A2 (en) * 2003-11-21 2005-06-09 Zymogenetics, Inc. Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
BRPI0516975A (pt) 2004-10-22 2008-09-30 Zymogenetics Inc anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno
AU2006212807A1 (en) * 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-IL-20, anti-IL-22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
JP5368301B2 (ja) 2006-06-22 2013-12-18 ノボ・ノルデイスク・エー／エス 可溶性ヘテロ二量体レセプター及びその使用
IN2012DN03025A (de) 2009-09-09 2015-07-31 Ct Se Llc
PE20130342A1 (es) 2010-04-15 2013-04-20 Spirogen Sarl Pirrolobenzodiacepinas y conjugados de las mismas
RU2626537C2 (ru) 2010-06-08 2017-07-28 Дженентек, Инк. Полученные с помощью генной инженерии антитела с цистеиновыми заменами и их конъюгаты
ES2544608T3 (es) 2010-11-17 2015-09-02 Genentech, Inc. Conjugados de anticuerpo y de alaninil-maitansinol
WO2012155019A1 (en) 2011-05-12 2012-11-15 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
EP2750713B1 (de) 2011-10-14 2015-09-16 Spirogen Sàrl Pyrrolobenzodiazepine und konjugate daraus
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
MX364329B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina.
ES2660029T3 (es) 2012-10-12 2018-03-20 Medimmune Limited Conjugados de anticuerpo-pirrolobenzodiazepinas
AU2013328628B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
KR101819404B1 (ko) 2012-10-12 2018-02-28 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
CN105102068B (zh) 2012-10-12 2018-06-01 Adc疗法责任有限公司 吡咯并苯并二氮杂卓-抗体结合物
PL2906253T3 (pl) 2012-10-12 2019-02-28 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało anty-psma
EP2906250B1 (de) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepin-anti-psma-antikörperkonjugate
CA2894959C (en) 2012-12-21 2022-01-11 Spirogen Sarl Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
CN110452242A (zh) 2012-12-21 2019-11-15 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
BR112015023070B1 (pt) 2013-03-13 2022-06-07 Genentech, Inc. Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica que compreende os mesmo, bem como seus usos para o tratamento de uma doença proliferativa
KR102066318B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EA201691023A1 (ru) 2013-12-16 2016-10-31 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
KR20160092024A (ko) 2013-12-16 2016-08-03 제넨테크, 인크. 1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법
MX371092B (es) 2013-12-16 2020-01-16 Genentech Inc Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos.
EP3149049B1 (de) 2014-05-27 2022-10-26 The University Of Queensland Il-22 zur verwendung in der behandlung von stoffwechselkrankheiten
EA037006B1 (ru) 2014-06-06 2021-01-26 Бристол-Майерс Сквибб Компани Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
KR20170052600A (ko) 2014-09-12 2017-05-12 제넨테크, 인크. 시스테인 가공된 항체 및 콘주게이트
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
AU2015317653A1 (en) 2014-09-17 2017-04-06 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
CN107206101B (zh) 2014-12-03 2021-06-25 基因泰克公司 季铵化合物及其抗体-药物缀合物
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
CA2988115A1 (en) 2015-06-03 2016-12-08 Bristol-Myers Squibb Company Anti-gitr antibodies for cancer diagnostics
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
ES2926969T3 (es) 2015-11-19 2022-10-31 Bristol Myers Squibb Co Anticuerpos contra el receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
PL3544636T3 (pl) 2017-02-08 2021-12-06 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
RS63502B1 (sr) 2017-04-18 2022-09-30 Medimmune Ltd Konjugati pirolobenzodiazepina
CA3057748A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
JP7274426B2 (ja) 2017-05-16 2023-05-16 ブリストル－マイヤーズ スクイブ カンパニー 抗ｇｉｔｒアゴニスト抗体での癌の処置
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
NZ761175A (en) 2017-08-18 2024-07-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
TW201920192A (zh) 2017-09-20 2019-06-01 韓商Ｐｈ製藥公司 泰蘭他汀（ｔｈａｉｌａｎｓｔａｔｉｎ）類似物
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
WO2020086858A1 (en) 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5436155A (en) * 1991-12-31 1995-07-25 Arch Development Corporation Isolated DNA encoding a somatostatin receptor
US5789192A (en) * 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
US5985614A (en) * 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000012708A2 (en) 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
JP2001510035A (ja) 1997-07-16 2001-07-31 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド インターロイキン−２０
US6486301B1 (en) * 1997-07-16 2002-11-26 Human Genome Sciences, Inc. Interleukin-20
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
WO1999007740A2 (en) 1997-08-06 1999-02-18 Zymogenetics, Inc. Lipocalin homologs
US6576743B1 (en) * 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
BR9814904A (pt) 1997-11-26 2000-10-03 Zymogenetics Inc Polinucleotìdeo isolado que codifica um polipeptìdeo, polipeptìdeo isolado, e, anticorpo.
IL137178A0 (en) 1998-01-23 2001-07-24 Immunex Corp Il-18 receptors
AU2871899A (en) 1998-03-09 1999-09-27 Schering Corporation Human receptor proteins; related reagents and methods
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
WO1999061630A2 (en) 1998-05-26 1999-12-02 Regeneron Pharmaceuticals, Inc. Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
WO2000039161A1 (en) 1998-12-31 2000-07-06 Millennium Pharmaceuticals, Inc. Class ii cytokine receptor-like proteins and nucleic acids encoding them
WO2000073457A1 (en) 1999-05-27 2000-12-07 Schering-Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
US6610286B2 (en) * 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
US7122632B2 (en) * 1999-12-23 2006-10-17 Zymogenetics, Inc. Soluble Interleukin-20 receptor
DE60030769T2 (de) * 1999-12-23 2007-10-25 Zymogenetics, Inc., Seattle Verfahren zur behandlung von entzündungen
JP4741139B2 (ja) * 1999-12-23 2011-08-03 ザイモジェネティクス， インコーポレイテッド 可溶性インターロイキン−２０レセプター
JP5015404B2 (ja) 2000-08-08 2012-08-29 ザイモジェネティクス， インコーポレイテッド 可溶性ｚｃｙｔｏｒ１１サイトカイン受容体
EP1803733B1 (de) * 2000-09-15 2010-03-10 ZymoGenetics, Inc. Polypeptide enthaltend extrazellulären Domäne von IL-20RA und/oderr IL-20RB
EP1390060A2 (de) 2001-01-26 2004-02-25 Eli Lilly And Company Verwendung von lp82 zur behandlung von störungen des körpergewichtes
WO2002070001A2 (en) 2001-02-28 2002-09-12 Eli Lilly And Company Use of lp82 to treat hematopoietic disorders
EP1399472B1 (de) 2001-03-09 2009-06-03 ZymoGenetics, Inc. Löslicher heterodimerer cytokinrezeptor
DE10154579A1 (de) 2001-11-07 2003-05-28 Medigene Ag Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen
US7582287B2 (en) 2001-12-17 2009-09-01 Zymogenetics, Inc. Method for treating cervical cancer
BRPI0408705A (pt) 2003-03-24 2006-03-07 Zymogenetics Inc método para produzir um anticorpo para um polipeptìdeo, anticorpo produzido pelo mesmo, anticorpo ou fragmento de anticorpo que se liga a um polipeptìdeo, métodos para reduzir ou inibir a proliferação ou diferenciação induzida pela il-20 de células hematopoiéticas e progenitores de célula hematopoiética, para reduzir a inflamação induzida pela il-20, para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero afligido com uma doença inflamatória, para tratar um condição patológica em um paciente associada com a atividade de il-20

Also Published As

Publication number Publication date
DK1351703T3 (da) 2006-11-27
EP1351703A2 (de) 2003-10-15
DE60121808T2 (de) 2007-03-29
ES2267814T3 (es) 2007-03-16
EP1803733A3 (de) 2007-10-31
DE60141546D1 (de) 2010-04-22
US7855269B2 (en) 2010-12-21
JP4908723B2 (ja) 2012-04-04
EP1351703B1 (de) 2006-07-26
EP1803733A2 (de) 2007-07-04
CA2422033A1 (en) 2002-03-21
JP2004525074A (ja) 2004-08-19
ATE460429T1 (de) 2010-03-15
EP1803733B1 (de) 2010-03-10
WO2002022153A3 (en) 2003-06-19
US20020085992A1 (en) 2002-07-04
WO2002022153A2 (en) 2002-03-21
US20110077207A1 (en) 2011-03-31
AU2001290837A1 (en) 2002-03-26
ATE333888T1 (de) 2006-08-15

Similar Documents

Publication Publication Date Title
DE60121808D1 (de) Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
IL189629A0 (en) Compositions containing human ctla-4 antibodies
ATE272650T1 (de) Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
DE60023870D1 (de) Verfahren zur herstellung von 3-aryloxy-3-arylpropylamine und deren zwischenprodukte
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
ATE224713T1 (de) Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression
MX9706969A (es) 3-(1,2,3,6-tetrahidropiridin-4-il)-1h-indoles y 3-(piperidin-4-il)-1h-indoles sustituidos en la posicion 5: agonistas del 5-ht1f novedosos.
ATE462006T1 (de) Isoform des vegfs
DE602004020657D1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
DE60331546D1 (de) Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung
DE60023860D1 (de) Verfahren zur herstellung von rekombinanten peptiden
PL322001A1 (en) 1-aryl-2-acetylamino ethane compounds, their application as antagonists of neurokinin, in particular of neurokinin 1
DE69328549D1 (de) Für einen humanen serotoninrezeptor (5-ht4b) kodierende dns und ihre verwendung
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
DK0840792T3 (da) (S)-hydroxynitrillyase fra Hevea brasiliensis
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE405577T1 (de) Lactam dipeptid und dessen verwendung zur inhibierung der beta-amyloid peptid frisetzung
ATE452903T1 (de) Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
DE60329115D1 (de) Tumorantigenprotein und dessen verwendung
ATE244760T1 (de) Wachtumsfaktor aus der harp-reihe, verfahren zu ihrer herstellung und verwendungen davon
EP1149844A3 (de) Verkürztes Reelin Protein und DNA kodierend für dasselbe
DE60321443D1 (de) Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung
ATE292970T1 (de) Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden
DE69519654D1 (de) htFIIIA Gen
EP1533378A3 (de) tks7, ein tyrosinkinase-substrat-protein

Legal Events

Date Code Title Description
8364 No opposition during term of opposition